RxC International’s whitepaper is designed to bring the reader’s attention to the value of innovation and risk management in biopharma commercialization. 
The authors present several important trends that profoundly impact the commercialization of novel treatments. These trends include the changing landscape of value-based healthcare, consumerism, personalized solutions, digital healthcare and emerging technologies and leveraging direct distribution models to improve supply chain efficiency. Furthermore, the article provides a framework of important questions to consider when addressing these trends as part of achieving commercial excellence.
The authors, Subbarao Jayanthi and Jose DeLeon have extensive leadership experience in new product development and commercialization in biopharma. RxC International is a premier life sciences management consulting firm with a passion for helping clients with growth strategies.